Literature DB >> 1711970

Practical aspects of the use of amiodarone.

P Puech1.   

Abstract

Amiodarone is a class III antiarrhythmic drug with sympatholytic properties, which prolongs the refractory period of all cardiac tissues, depresses sinus node automaticity and atrioventricular nodal conduction. It is active on all cardiac arrhythmias, its use being limited by the risk of side effects, mainly extracardiac, which are dependent upon dosage and duration of treatment. The use of an oral loading dose of intravenous infusion to rapidly obtain an efficacious blood concentration may minimise the delay in onset of drug action. Amiodarone progressively accumulates in cardiac muscle and is eliminated slowly, allowing drug free periods (2 days a week) on long term therapy. Pharmacokinetic interaction with digoxin, class I antiarrhythmic drugs and warfarin must be considered during combination therapy, as well as the potentiation of electrophysiological effects when amiodarone is co-administered with combined calcium antagonists and beta-blockers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711970     DOI: 10.2165/00003495-199100412-00009

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  25 in total

1.  Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases.

Authors:  A Bayés de Luna; P Coumel; J F Leclercq
Journal:  Am Heart J       Date:  1989-01       Impact factor: 4.749

2.  Drug interactions with amiodarone.

Authors:  F I Marcus
Journal:  Am Heart J       Date:  1983-10       Impact factor: 4.749

3.  Arrhythmia in hypertrophic cardiomyopathy. II: Comparison of amiodarone and verapamil in treatment.

Authors:  W J McKenna; L Harris; G Perez; D M Krikler; C Oakley; J F Goodwin
Journal:  Br Heart J       Date:  1981-08

4.  Amiodarone increases plasma digoxin concentrations.

Authors:  J O Moysey; N S Jaggarao; E N Grundy; D A Chamberlain
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-24

5.  Dangers of amiodarone and anticoagulant treatment.

Authors:  A Rees; J J Dalal; P G Reid; A H Henderson; M J Lewis
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-30

6.  Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia.

Authors:  A N Mooss; S M Mohiuddin; T T Hee; D J Esterbrooks; D E Hilleman; K S Rovang; M H Sketch
Journal:  Am J Cardiol       Date:  1990-03-01       Impact factor: 2.778

7.  Clinical efficacy and electropharmacology of continuous intravenous amiodarone infusion and chronic oral amiodarone in refractory ventricular tachycardia.

Authors:  S Saksena; S T Rothbart; Y Shah; G Cappello
Journal:  Am J Cardiol       Date:  1984-08-01       Impact factor: 2.778

8.  Use of intravenous amiodarone for emergency treatment of life-threatening ventricular arrhythmias.

Authors:  I Helmy; J M Herre; G Gee; H Sharkey; P Malone; M J Sauve; J C Griffin; M M Scheinman
Journal:  J Am Coll Cardiol       Date:  1988-10       Impact factor: 24.094

9.  Hypotensive action of commercial intravenous amiodarone and polysorbate 80 in dogs.

Authors:  W B Gough; R H Zeiler; P Barreca; N El-Sherif
Journal:  J Cardiovasc Pharmacol       Date:  1982 May-Jun       Impact factor: 3.105

10.  Intravenous amiodarone in the acute treatment of recurrent symptomatic ventricular tachycardia.

Authors:  F Morady; M M Scheinman; E Shen; W Shapiro; R J Sung; L DiCarlo
Journal:  Am J Cardiol       Date:  1983-01-01       Impact factor: 2.778

View more
  2 in total

Review 1.  Perioperative management of drug therapy, clinical considerations.

Authors:  M S Smith; H Muir; R Hall
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

Review 2.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.